Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has collaboration agreements with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer; LetsGetChecked to track COVID-19 variants in California; and Merck & Co., Inc. to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency. The company was incorporated in 1998 and is headquartered in San Diego, California. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Dadswell Charles | SVP & General Counsel | Apr 28 | Sale | 300.13 | 368 | 110,448 | 7,427 | May 02 04:54 PM | Hoyt Aimee L | SVP, Chief People Officer | Apr 12 | Sale | 350.51 | 2,474 | 867,173 | 5,342 | Apr 14 04:33 PM | Febbo Phillip G. | SVP Chief Medical Officer | Apr 06 | Sale | 360.01 | 1,988 | 715,700 | 5,774 | Apr 07 04:19 PM | Dadswell Charles | SVP & General Counsel | Mar 28 | Sale | 342.83 | 368 | 126,161 | 7,795 | Mar 30 07:02 PM | Hoyt Aimee L | SVP, Chief People Officer | Feb 22 | Option Exercise | 0.00 | 3,421 | 0 | 6,678 | Feb 24 05:36 PM | TOUSI SUSAN H | SVP, Chief Commercial Officer | Feb 22 | Option Exercise | 0.00 | 4,561 | 0 | 43,891 | Feb 24 05:42 PM | deSouza Francis A | President and CEO | Feb 22 | Option Exercise | 0.00 | 19,383 | 0 | 88,587 | Feb 24 05:43 PM | Febbo Phillip G. | SVP Chief Medical Officer | Feb 22 | Option Exercise | 0.00 | 2,851 | 0 | 5,866 | Feb 24 05:32 PM | SAMAD SAM | SVP and CFO | Feb 22 | Option Exercise | 0.00 | 4,561 | 0 | 11,023 | Feb 24 05:39 PM | Pegels Kevin Carl | Chief of Global Operations | Feb 22 | Option Exercise | 0.00 | 1,065 | 0 | 5,910 | Feb 24 05:38 PM | GOSWAMI JOYDEEP | SVP Corp Business Development | Feb 22 | Option Exercise | 0.00 | 3,979 | 0 | 7,824 | Feb 24 05:34 PM | Dadswell Charles | SVP & General Counsel | Feb 22 | Option Exercise | 0.00 | 4,561 | 0 | 7,889 | Feb 24 05:30 PM | TOUSI SUSAN H | SVP, Chief Commercial Officer | Jan 12 | Sale | 425.00 | 800 | 340,000 | 39,274 | Jan 13 04:48 PM | TOUSI SUSAN H | SVP, Chief Commercial Officer | Dec 28 | Sale | 387.06 | 100 | 38,706 | 40,074 | Dec 30 04:10 PM | Dadswell Charles | SVP & General Counsel | Dec 22 | Sale | 380.29 | 322 | 122,453 | 3,283 | Dec 23 05:37 PM | TOUSI SUSAN H | SVP, Chief Commercial Officer | Dec 08 | Sale | 375.00 | 100 | 37,500 | 40,174 | Dec 09 04:32 PM | Dadswell Charles | SVP, General Counsel | Nov 22 | Sale | 377.86 | 314 | 118,648 | 3,605 | Nov 24 04:16 PM | Aravanis Alexander | SVP, Chief Technology Officer | Nov 12 | Sale | 386.35 | 361 | 139,472 | 4,127 | Nov 16 04:52 PM | Febbo Phillip G. | SVP Chief Medical Officer | Nov 08 | Sale | 406.83 | 1,000 | 406,830 | 3,015 | Nov 09 04:59 PM | Aravanis Alexander | SVP, Chief Technology Officer | Nov 02 | Sale | 412.78 | 2,926 | 1,207,801 | 4,679 | Nov 04 06:11 PM | TOUSI SUSAN H | SVP, Chief Commercial Officer | Oct 28 | Sale | 414.35 | 100 | 41,435 | 41,256 | Nov 01 04:33 PM | Aravanis Alexander | SVP, Chief Technology Officer | Oct 26 | Sale | 423.00 | 2,926 | 1,237,698 | 7,605 | Oct 28 05:27 PM | Dadswell Charles | SVP & General Counsel | Oct 22 | Sale | 411.00 | 314 | 129,054 | 4,658 | Oct 26 04:48 PM | Aravanis Alexander | SVP, Chief Technology Officer | Oct 19 | Sale | 411.82 | 2,926 | 1,204,972 | 10,531 | Oct 21 05:50 PM | Aravanis Alexander | SVP, Chief Technology Officer | Oct 12 | Sale | 409.21 | 2,926 | 1,197,350 | 13,457 | Oct 14 06:29 PM | TOUSI SUSAN H | SVP, Chief Commercial Officer | Sep 28 | Sale | 418.04 | 100 | 41,804 | 41,356 | Sep 30 04:04 PM | Dadswell Charles | SVP & General Counsel | Sep 22 | Sale | 436.69 | 314 | 137,121 | 4,972 | Sep 23 04:24 PM | TOUSI SUSAN H | SVP, Chief Commercial Officer | Aug 30 | Sale | 463.50 | 300 | 139,050 | 41,456 | Sep 01 07:15 PM | Dadswell Charles | SVP & General Counsel | Aug 23 | Sale | 489.10 | 314 | 153,577 | 5,286 | Aug 25 04:40 PM | TOUSI SUSAN H | SVP, Chief Commercial Officer | Aug 04 | Sale | 500.00 | 1,000 | 500,000 | 41,756 | Aug 05 04:22 PM | Hoyt Aimee L | SVP, Chief People Officer | Aug 04 | Sale | 500.00 | 372 | 186,000 | 3,757 | Sep 08 07:36 PM | TOUSI SUSAN H | SVP, Chief Commercial Officer | Jul 28 | Sale | 486.41 | 300 | 145,923 | 42,743 | Jul 29 04:34 PM | Dadswell Charles | SVP & General Counsel | Jul 22 | Sale | 482.23 | 314 | 151,420 | 5,576 | Jul 26 04:57 PM | Aravanis Alexander | SVP, Chief Technology Officer | Jul 07 | Sale | 477.59 | 539 | 257,421 | 4,679 | Jul 07 06:26 PM | TOUSI SUSAN H | SVP, Chief Commercial Officer | Jun 28 | Sale | 478.95 | 300 | 143,685 | 43,043 | Jun 30 05:27 PM | Hoyt Aimee L | SVP, Chief People Officer | Jun 24 | Sale | 475.00 | 500 | 237,500 | 4,111 | Sep 08 07:36 PM | Dadswell Charles | SVP & General Counsel | Jun 22 | Sale | 461.01 | 314 | 144,757 | 5,890 | Jun 24 05:41 PM | Febbo Phillip G. | SVP Chief Medical Officer | Jun 11 | Sale | 447.59 | 1,000 | 447,588 | 4,461 | Jun 14 05:50 PM | DORSA CAROLINE | Director | Jun 10 | Sale | 450.00 | 1,000 | 450,000 | 8,501 | Jun 14 05:48 PM | Hoyt Aimee L | SVP, Chief People Officer | Jun 10 | Sale | 450.00 | 500 | 225,000 | 4,611 | Sep 08 07:36 PM | Dadswell Charles | SVP & General Counsel | May 24 | Sale | 403.04 | 314 | 126,555 | 6,204 | May 26 04:50 PM | TOUSI SUSAN H | SVP, Chief Commercial Officer | May 20 | Sale | 400.00 | 500 | 200,000 | 43,343 | May 24 04:43 PM | FLATLEY JAY T | Director | May 18 | Sale | 379.53 | 4,000 | 1,518,120 | 148,933 | May 20 04:51 PM |
|